Dr. Reddy's Laboratories Ltd. Press Release Jul 13 2026
Filed with NSE · · 2 pages · English
Watch Dr. Reddy's Laboratories' latest callDr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings Call · Replay · Oct 23Read the transcript of Dr. Reddy's Laboratories (NSE:DRREDDY) Q2 2027 Earnings CallDr. Reddy's Laboratories Ltd. on 6ix
Earlier from Dr. Reddy's Laboratories
- Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F
- Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
- Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)
- Press Release May 28 2026
- Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
Later from Dr. Reddy's Laboratories
- Dr. Reddy's Laboratories Ltd. Press Release Jul 23 2026
- Dr. Reddy's Laboratories Ltd. Press Release Aug 01 2026
- Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
- Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 07, 2026, titled "Intimation of Earnings call".
- Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Dr. Reddy s Receives DCGI Approval for Zytorvi® (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India.".
Follow Dr. Reddy's Laboratories into a list and get an email when it puts out news.
Follow Dr. Reddy's Laboratories